Track 02 of 9
Alzheimer’s & Dementia
Anti-amyloid therapies, biomarkers and early detection.
The approval of lecanemab and donanemab has transformed Alzheimer’s disease into a treatable condition for patients with early symptomatic disease and confirmed amyloid pathology. GCNN 2027 will present long-term CLARITY-AD and TRAILBLAZER-ALZ open-label extension data, real-world ARIA-E and ARIA-H rates stratified by APOE4 status, and operational models for safe infusion-clinic delivery. Sessions will examine the rapid emergence of plasma p-tau217 as a triage biomarker rivaling CSF and amyloid-PET, the next-wave tau-directed therapeutics, and GLP-1 receptor agonists (evoke, evoke+) as a potential disease-modifying class.
Focus areas
- Lecanemab and donanemab: long-term efficacy, ARIA monitoring, APOE4 stratification
- Plasma p-tau217 and the blood biomarker triage pathway
- Tau-directed therapeutics: antisense oligonucleotides and active immunotherapy
- GLP-1 receptor agonists in neurodegeneration: evoke, evoke+ readouts
- Lewy body and frontotemporal dementia: TDP-43 and progranulin programs
- Subcutaneous lecanemab and at-home administration models
- Preclinical AD: DIAN-TU, AHEAD 3-45 and primary prevention